Sensitivities of methods for PD-L1, CD8, and CD4 biomarkers, in patients with melanoma, were from 84.31% to 97.30%, and specificities of these analyzed biomarkers in melanoma tumor microenvironment cells were from 86.67% to 96.97%, offering the possibility to be biomarkers with predictive accuracy in melanomas. The gene discussed is CD4; the disease is neoplasm.